A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma

NCT03504696 ·Status: COMPLETED

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

NCT05115006 ·Status: COMPLETED

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159 ·Status: RECRUITING ·Phase: PHASE2

Radiation and Combination Immunotherapy for Melanoma

NCT03850691 ·Status: COMPLETED ·Phase: PHASE2

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

NCT06566391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

NCT01455103 ·Status: WITHDRAWN ·Phase: PHASE1

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

NCT01245556 ·Status: COMPLETED ·Phase: PHASE1

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692 ·Status: COMPLETED ·Phase: PHASE2

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

NCT01511913 ·Status: COMPLETED

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

NCT04526899 ·Status: COMPLETED ·Phase: PHASE2

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

NCT02905266 ·Status: COMPLETED ·Phase: PHASE3

A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US

NCT03732560 ·Status: COMPLETED

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045 ·Status: TERMINATED ·Phase: PHASE2

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

NCT01740297 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

NCT00942162 ·Status: COMPLETED ·Phase: PHASE2

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

NCT03329846 ·Status: COMPLETED ·Phase: PHASE3

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

NCT02673970 ·Status: RECRUITING

Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma

NCT02694965 ·Status: COMPLETED

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

NCT01703507 ·Status: COMPLETED ·Phase: PHASE1

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

NCT04698187 ·Status: TERMINATED ·Phase: PHASE2